5-year DFS (%) | 5-year OS (%) | |
---|---|---|
92.8 | 98.4 | |
92.9 vs. 90.1 | 98.4 vs. 97.0 | |
92.1 vs. 90.1 | 97.1 vs. 97.8 | |
85.3 | 94.7 |
Lymph node negative (N = 2114, 64 %) | Lymph node positive (N = 1214, 36%) |
---|---|
G1, tumor size > 3 cm | G1, tumor size >2 cm |
G2, tumor size > 2 cm | G2, any size |
G3, tumor size > 1 cm | G3, any size |
TEST | ASCO | NCCN | ESMO* | St Gallen Group* | EGTM |
---|---|---|---|---|---|
Ln - , strong | Ln Ln -, +, 1 2A | IB | Yes | Ln +/- | |
Ln Ln -, +, strong moderate | Ln -/+, 1 | IB | Yes | Ln +/- | |
Ln -, moderate | Ln -/+, 2A | IB | Yes | Ln +/- | |
Ln -, moderate | Ln -/+, 2A | IB | Yes | Ln +/- | |
Ln -, moderate | Ln NR, 2A | no | Yes | Ln - |
9-year DFS (%) | 9-year OS (%) | |
---|---|---|
84 | 93.7 | |
83.3 | 93.9 | |
84.3 | 93.8 | |
75.7 | 89.3 |
Study | RS low (%) | RS intermediate (%) | RS high (%) |
---|---|---|---|
40 | 28 | 32 | |
52 | 31 | 17 | |
57 | 36 | 7 | |
53 | 36 | 10 | |
19 | 63 | 19 |
Risk groups | Percentage N (%) | Treatment regimen |
---|---|---|
2745 (41.0) | no chemotherapy | |
592 (8.8) | randomization: chemotherapy vs no | |
1550 (23.2) | randomization: chemotherapy vs no | |
1806 (27.0 ) | chemotherapy |